WELCOME TO

Specialist Communications for Life Sciences
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.

Our
Services
Focused on supporting life science companies to raise their profile, build corporate value, and generate interest, the services we provide include:
PR & Media
- Press releases
- Article writing and placement
- Media interviews
- Messaging
- Copy writing
- Social media
- Media training
- Events
Marketing
- Conference, event and trade show support
- Marketing literature
- Market research
- Campaign development
- Advertising
- Sponsorship
- Product launches
Design & Branding
- Website design and development
- Print collateral development
- Identity and logo creation
- Brand strategy
- Presentation development
- Video production
Investor Relations
- Business plan development
- Presentation development
- PR targeting the life science trade press read by investors

The
Team
An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.
EVENTS
-
Milner Therapeutics Symposium 2026
-
ON Helix 2026 – Disrupting Bio Innovation
-
BioForward 2026
-
ELRIG Drug Discovery 2026
Tecan accelerates Data-Driven Lab journey with Agentic AI developments powered by NVIDIA
Männedorf, Switzerland, June 24, 2026: Tecan (SIX Swiss Exchange: TECN), a global provider of laboratory automation and solutions, today announced the integration of Agentic AI capabilities into its lab analytics [...]
FairJourney Bio and AbTherx Partner to Offer Fully Integrated Antibody Discovery
FairJourney Bio brings AbTherx’s Atlas transgenic mouse technologies in-house, enabling partner programmes to run from immunisation to a developability-assessed lead in one continuous workflow Partnership announced at BIO International Convention [...]
TRIMTECH Therapeutics brings total seed round to $47M with additional investment of $14M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio
Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), and BGF join existing investors Cambridge Innovation Capital, DDF, M Ventures, Pfizer Ventures, Eli Lilly [...]





















